Latest Blogs

Feb 23, 2021
In their roles as patient advocates, Ms. Janine Guglielmino and Dr. Sue Friedman have observed growing patient confusion about breast cancer subtypes and the difference between acquired and inherited gene mutations.
Feb 18, 2021
This is a time of significant and multi-layered anxiety, especially for our patients living with and beyond cancer. 
Feb 11, 2021
"My motto is to stand up for all the people who face casual racism, sexism, and injustice, and my aim is to protect international trainees in medicine when it is my turn to be a mentor," Dr. Viju Chandrasekhar affirms as she shares a personal experience with bias based on her accent.
Feb 11, 2021
Our oncology training is shaped by those who devote their time to helping us turn our weaknesses into strengths, and all of us have a role to play as teachers.
Subscribe to this column

Clifford A. Hudis, MD, FACP, FASCO

Clifford A. Hudis, MD, FACP, FASCO, is the CEO of ASCO, executive vice chair of Conquer Cancer, the ASCO Foundation, and chair of CancerLinQ. Prior to these roles, he served as chief of the Breast Medicine Service and an attending physician at Memorial Sloan Kettering Cancer Center and as a professor in the Department of Medicine at Weill Cornell Medical College. He is a past president of ASCO. His research interests include all areas of care related to breast cancer, with a focus on the development of novel systemic therapies and prevention interventions related to obesity and inflammation. Follow Dr. Hudis on Twitter @CliffordHudis.

Disclosure.

Feb 04, 2020
As we celebrate the 20th anniversary of World Cancer Day this February 4, it’s important to recognize that we are making progress in addressing cancer.
Jan 16, 2020
As the world’s leading organization of oncology professionals who care for people with cancer, ASCO believes it is critical to understand what the public, including patients, think of, expect, and need from the nation’s cancer care system.
Oct 16, 2019
Participants in ASCO's Advocacy Summit discuss the importance of being engaged with health policy to improve the lives of people affected by cancer.
Oct 04, 2019
About 42 million Medicaid patients do not have the guaranteed ability to participate in clinical trials.
May 20, 2019
Dr. Ward and I discuss the policies that public and private insurers use to control the use of anticancer drug therapies, such as prior authorization requirements, restrictive formularies, step therapy, or fail first requirements, and specialty specific tiers.
Mar 26, 2019
Dr. Sharpless joined me to talk about pediatric cancer research, clinical trial methodology, eligibility criteria, and more.

Pages